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Abstract
Myocardial infarction (MI) is a common complex disease with a genetic component. While several single nucleotide
polymorphisms (SNPs) have been reported to be associated with risk of MI, they do not fully explain the observed genetic
component of MI. We have been investigating the association between MI and SNPs that are located in genes and have the
potential to affect gene function or expression. We have previously published studies that tested about 12,000 SNPs for
association with risk of MI, early-onset MI, or coronary stenosis. In the current study we tested 17,576 SNPs that could affect gene
function or expression. In order to use genotyping resources efficiently, we staged the testing of these SNPs in three case–control
studies of MI. In the first study (762 cases, 857 controls) we tested 17,576 SNPs and found 1,949 SNPs that were associated with MI
(P,0.05). We tested these 1,949 SNPs in a second study (579 cases and 1159 controls) and found that 24 SNPs were associated
with MI (1-sided P,0.05) and had the same risk alleles in the first and second study. Finally, we tested these 24 SNPs in a third
study (475 cases and 619 controls) and found that 5 SNPs in 4 genes (ENO1, FXN (2 SNPs), HLA-DPB2, and LPA) were associated
withMI in the third study (1-sided P,0.05), and had the same risk alleles in all three studies. The false discovery rate for this group
of 5 SNPs was 0.23. Thus, we have identified 5 SNPs that merit further examination for their potential association with MI. One of
these SNPs (in LPA), has been previously shown to be associated with risk of cardiovascular disease in other studies.
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Introduction
Myocardial infarction (MI) is a prevalent and often fatal
consequence of coronary heart disease. Each year approximately
865 thousand Americans are diagnosed with MI and about 180
thousand die from the disease [1]. MI occurs when thrombosis—
precipitated by ruptured or eroded atherosclerotic plaque—leads
to acute ischemia and subsequent necrosis of the myocardium.
Risk factors for MI include age, sex, elevated LDL-cholesterol,
hypertension, low HDL-cholesterol, smoking, type 2 diabetes, and
family history of cardiovascular disease. Risk of MI has a genetic
component as evidenced by large twin studies [2] which showed
that death from cardiovascular disease is more highly correlated
among identical twins than fraternal twins. Among genetic
variants that are associated with MI, some can affect traditional
risk factors [3,4] but for others the underlying biological
explanation for the association is not known [5,6].
The identification of genetic variants that are associated with
MI is a challenging task, because variants that are associated with
MI are expected to only modestly increase the risk of MI, and
because a large number of variants could potentially be tested.
Thus, very large studies are needed to detect modest association
and account for multiple testing confidently [7]. We have limited
the magnitude of multiple testing in the past [8–10] by testing
SNPs with high prior probability for association with MI.
Previously, we described the results from investigating ,12,000
such SNPs [8–10]. Here we asked if we could identify SNPs that
are associated with MI by investigating ,17,000 SNPs. We
identified 5 SNPs that appear to be associated with MI and should
be investigated in additional studies of MI.
Methods
Objectives
To identify genetic polymorphisms associated with MI, we
interrogated three case–control studies comprising cases with a
history of MI and controls without a history of MI. The first two
case–control studies (Study 1 and Study 2) identified SNPs
nominally associated with MI. The hypotheses that these SNPs
are associated with MI were tested in Study 3. We determined the
allele frequency of each SNP in pools of case and control DNA
prior to determining the genotype of a smaller number of SNPs for
all individual DNA samples.
Participants
Participants in Study 1 and Study 2 were enrolled between July
1989 and May 2005 by the University of California, San Francisco
(UCSF) Genomic Resource in Arteriosclerosis. UCSF samples
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received at the Celera genotyping facility by May 2004 were
considered for inclusion in Study 1. Samples that arrived past that
date were considered for Study 2. Cases in Study 1 and Study 2
included patients who had undergone diagnostic or interventional
cardiac catheterization and patients of the UCSF Lipid Clinic.
Controls were enrolled by the UCSF Genomic Resource in
Arteriosclerosis and included UCSF staff, patients of UCSF Clinics,
and senior citizens who participated in physical activities at regional
community centers and events for senior citizens. A history of MI for
Study 1 cases was verified by a clinical chart review or by The
International Classification of Diseases, 9th Revision (ICD9) codes 410 or
411 in the patient records. MI status for Study 2 cases was
determined by ICD9 codes 410 or 411 or by a self-reported history
of MI. To characterize the accuracy of these self–reported histories,
medical record review for a sample of Study 2 cases resulted in
verification of the self–reported MI status for 98% of the sample
(verification by electrocardiogram, cardiac enzymes or imaging).
Controls had no history of MI, diabetes or symptomatic vascular
disease. All participants of Study 1 and Study 2 chose Caucasian as
their ethnicity in response to a multiple-choice questionnaire.
Participants in Study 3 were patients of the Cleveland Clinic
Foundation (CCF) Heart Center who had undergone diagnostic or
interventional cardiac catheterization between July 2001 and
March 2003 and enrolled in the Genebank at Cleveland Clinic
Study. A history of MI was verified by electrocardiogram, cardiac
enzymes, or perfusion imaging. Controls had less than 50%
coronary luminal narrowing. All participants in Study-3 selected
North European, Eastern European, or ‘other Caucasian’ as the
description of both their mother and father on the enrollment
questionnaire. The demographic and risk factor characteristics of
the participants in the 3 studies are presented in Table 1.
SNP Selection
The 17,576 SNPs investigated in Study 1 are located in 10,152
genes. Of these 17,576 SNPs, 2767 were tested in at least one of 3
previously reported studies [8–10]. We previously reported that
one of these SNPs (rs3798220 in LPA) was associated with
cardiovascular disease [10]. Most of these SNPs (65%) could
potentially affect gene function or expression because they cause
an amino-acid change in a predicted open reading frame (missense
SNPs), or they are located in exon acceptor or donor splice site,
and could change the splicing pattern of predicted open reading
frames. We also considered as potentially functional some SNPs
that are located in regions that are known to be involved in
transcriptional regulation (predicted transcription factor binding
sites), or RNA stability (39 or 59 untranslated regions, or predicted
microRNA binding sites).
Allele Frequency and Genotype Determination
Initially, the allele frequency for each individual SNP was
determined for all the cases and all the controls in pools of DNA.
Pools were made by mixing equal volumes of standardized DNA
from each individual member of the pool. Prior to pooling, DNA
concentration for each sample was determined in triplicate using
Picogreen fluorescent detection (Invitrogen). Measurements were
repeated for samples which had high variation of fluorescence values
(5% or greater coefficient of variation). DNA concentrations were
determined from mean fluorescence values using a standard curve of
salmon sperm DNA. DNA samples were then diluted to 6 ng/mL
using automated liquid handling robotics (Beckman Coulter Fx, or
Perkin Elmer Multiprobe II). The final concentration was confirmed
using Picogreen fluorescent detection. Typically, several unique
pools of DNA were made for cases and controls, made up of about
50 cases or controls. For each SNP, two real-time PCR reactions
were performed, using 3 ng of pooled DNA in each reaction and
allele-specific primers. The allele frequency in each pool was
calculated from amplification curves for each allele. Genotyping of
individual DNA samples was done by performing two real-time PCR
reactions for each individual sample, using 0.3 ng DNA from each
sample and allele specific primers.
Ethics
Subjects of all three studies gave written informed consent and
completed questionnaire approved by the Institutional Review
Table 1. Risk factors for MI in three case–control studies
Study 1 Study 2 Study 3
Cases
(n=762)
Controls
(n =857)
Cases
(n=579)
Controls
(n =1159)
Cases
(n=475)
Controls
(n =619)
Male, % 60 41 81 42 61 62
Age at enrollment, median (range) 62 (29–87) 65 (24–100) 66(28–88) 58 (45–97) 60 (32–86) 58 (37–88)
Age at MI, median (range) 52 (27–82) NA 57 (21–70) NA 53 (29–77) { NA
Smoking, % 66 45 68 40 73 54
Diabetes, % 20 0{ 25 0{ 38 10
Dyslipidemia1, % 84 53 84 61 95 56
Hypertension||, % 61 32 66 33 96 78
BMI (kg/m2), mean6SD 2865 2665 2865 2665 3166 3067
{Data available for 254 cases.
{Individuals with diabetes were excluded from control group.
1Dyslipidemia was defined in Study 1 and Study 2 to be self-reported history of a physician diagnosis of dyslipidemia or the use of lipid lowering prescription
medication(s) and defined in Study 3 to be the use of lipid lowering prescription medication(s), LDL cholesterol .129 mg/dL, triglycerides .149 mg/dL or HDL
cholesterol ,45 mg/dL .
||Hypertension was defined in Study 1 and Study 2 to be a self–reported history of a physician diagnosis of hypertension or use of antihypertensive prescription
medication(s) and defined in Study 3 to be the use of antihypertensive prescription medication(s), systolic blood pressure .160 mmHg, or diastolic blood pressure
.90 mmHg.
NA; not applicable.
doi:10.1371/journal.pone.0002895.t001
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Board of UCSF (Study 1 and Study 2) or the Cleveland Clinic
Foundation (Study 3).
Statistical methods
We assessed association between MI status and allele frequen-
cies by two-tailed x2 tests, and between MI status and genotype by
logistic regression using an additive inheritance model (Wald test).
In Study 2 and Study 3, since we tested a single prespecified risk
allele for each SNP, we present one-sided P values and 90%
confidence intervals (for odds ratios greater than one, there is 95%
confidence that the true risk estimate is greater than the lower
bound of a 90% confidence interval). We used a P threshold value
of 0.05 in all three studies, and adjusted for multiple testing by
calculating the False discovery rate (FDR) in Study 3. FDR was
calculated using the MULTTEST procedure (SAS statistical
package Version 9.1); for SNPs that were in the same gene, only
the SNP with the higher (less significant) P value was included in
the calculation.
Results
We measured the allele frequencies of 17,576 putative functional
SNPs in Study 1 cases and controls using pooled DNA samples and
identified 1,949 SNPs that were associated with MI (P,0.05) and
had minor allele frequency estimates that were greater than 1%. For
these 1,949 SNPs, we determined allele frequencies in Study 2 cases
and controls using pooled DNA samples and verified that the risk
allele identified in Study 1 was also associated with risk of MI in
Study 2. For those SNPs that were associated with MI and had the
same risk alleles in both pooling studies, we then confirmed the
association of the SNP with MI in Study 1 and Study 2 by
genotyping individual DNA samples.We found that the risk alleles of
24 SNPs in 23 genes were associated withMI in both studies using an
additive inheritance model (Table 2) and a P value threshold of 0.05.
Next we tested the hypotheses that the risk alleles of these 24 SNPs
would be associated with MI in Study 3. The power to detect
association with MI for these 24 SNPs (based on the risk and allele
frequency observed in Study 2) ranged from 41% (for rs3812475 in
TRMT12) to 83% (for rs725660 in LOC388553). We found that the
risk allele of 5 SNPs, in 4 genes (ENO1, FXN (2 SNPs), HLA-DPB2,
and LPA) were associated with MI using an additive inheritance
model after adjustment for age and sex (Table 3). The false discovery
rate for these 5 SNPs was 0.23. The distribution of the genotypes for
each of the SNPs did not deviate from what was expected under
Hardy-Weinberg equilibrium (P.0.5). Further adjustment for
traditional risk factors (dyslipidemia, hypertension, smoking status,
and BMI), did not appreciably change the risk estimate for 4 of these
SNPs (Table 3, LPA, FXN (2 SNPs), and HLA-DPB2). However, the
risk for the ENO1 SNP was not statistically significant after further
adjustment for traditional risk factors (OR=1.09, 90% CI 0.85–
Table 2. Twenty four SNPs associated with MI in Study 1 and Study 2
SNP Gene Symbol Risk Allele Study 1 Study 2
Risk Allele
Freq. P value OR 95%CI
Risk Allele
Freq. P value* OR 90%CI
rs11568658 ABCC4 G 0.97 0.005 1.98 1.24–3.16 0.97 0.01 1.81 1.19–2.77
rs16875009 ADAMTS16 A 0.13 0.005 1.33 1.09–1.62 0.13 0.005 1.29 1.10–1.51
rs25651 ANPEP T 0.29 0.0001 1.36 1.17–1.58 0.31 0.02 1.17 1.03–1.33
rs439401 APOE T 0.35 0.03 1.17 1.01–1.35 0.37 0.01 1.19 1.05–1.35
rs867852 C1orf81 T 0.78 0.03 1.22 1.02–1.45 0.78 0.04 1.17 1.01–1.37
rs28372907 DHX33 A 0.18 0.03 1.21 1.02–1.44 0.18 0.01 1.22 1.05–1.42
rs11553576 EML3 T 0.60 0.03 1.17 1.02–1.35 0.60 0.03 1.16 1.02–1.31
rs1325920 ENO1 A 0.80 0.02 1.24 1.03–1.48 0.80 0.007 1.26 1.08–1.48
rs31208 FAM71B G 0.11 0.03 1.27 1.03–1.57 0.12 0.006 1.30 1.09–1.55
rs3793456 FXN G 0.56 0.01 1.20 1.05–1.39 0.55 0.03 1.15 1.02–1.30
rs10890 FXN T 0.43 0.004 1.23 1.07–1.42 0.43 0.03 1.15 1.02–1.30
rs35410698 HLA-DPB2 G 0.93 0.02 1.43 1.06–1.91 0.94 0.006 1.53 1.16–2.03
rs1136141 HSPA8 G 0.86 0.05 1.24 1.00–1.53 0.86 0.02 1.26 1.05–1.52
rs7928656 KCTD14 A 0.84 0.04 1.23 1.01–1.51 0.84 0.004 1.32 1.11–1.57
rs3740918 KIRREL3 G 0.69 0.003 1.26 1.08–1.46 0.70 0.01 1.20 1.05–1.37
rs725660 LOC388553 A 0.34 0.006 1.23 1.06–1.42 0.35 0.0009 1.26 1.12–1.43
rs3798220 LPA C 0.02 0.04 1.59 1.03–2.48 0.02 0.008 1.72 1.19–2.49
rs11711953 MAP4 T 0.07 0.03 1.34 1.03–1.73 0.07 0.01 1.35 1.09–1.67
rs4907956 OLFM3 G 0.60 0.03 1.18 1.02–1.36 0.61 0.01 1.19 1.05–1.34
rs2290819 PTPRM T 0.38 0.03 1.17 1.01–1.35 0.38 0.008 1.20 1.06–1.35
rs3204635 STAC3 A 0.25 0.02 1.20 1.03–1.40 0.26 0.03 1.16 1.02–1.33
rs1866389 THBS4 C 0.20 0.03 1.21 1.02–1.43 0.20 0.03 1.19 1.03–1.37
rs3812475 TRMT12 T 0.50 0.03 1.16 1.01–1.34 0.52 0.04 1.13 1.01–1.28
rs862708 ZNF304 C 0.02 0.003 1.88 1.24–2.83 0.03 0.03 1.45 1.05–2.00
*1 sided P value
doi:10.1371/journal.pone.0002895.t002
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1.38, P= 0.28). Dyslipidemia could be confounding the association
of the ENO1 SNP withMI since this SNP trended toward association
with dyslipidemia (P=0.1).
Discussion
We conducted an analysis of 17,576 SNPs that could potentially
affect gene function or expression in three case-control studies of
MI and identified 5 SNPs in four genes (ENO1, FXN (2 SNPs),
HLA-DPB2, and LPA) that were associated with MI. The false
discovery rate for this group of 5 SNPs was 0.23, indicating that
several of these SNPs are expected to be associated with MI.
The first SNP is located in ENO1, a gene that encodes a-
enolase, a glycolytic enzyme that catalyzes the conversion of 2-
phospho-D-glycerate to phosphoenolpyruvate. a-enolase is also
known to be a plasminogen receptor on the surface of
hematopoietic cells and endothelial cells [11]. Thus, a-enolase
could contribute to fibrinolysis, hemostasis, and arterial thrombus
formation–processes that are critical in the pathophysiology of MI.
The SNP in ENO1 (rs1325920) is located about 1 kb upstream of
the gene and could be involved in transcriptional regulation.
Two of the SNPs are in the FXN gene. The FXN gene encodes
Frataxin, a mitochondrial protein involved in maintaining cellular
iron homeostasis [12]. Expanded GAA triplet repeats in intron 1
of FXN leads to silencing of the FXN gene and to accumulation of
iron in the mitochondria, which makes mitochondria sensitive to
oxidative stress [13]. These changes lead to Friedreich’s ataxia, an
autosomal recessive disease of the central nervous system that is
frequently associated hypertrophic cardiomyopathy [12]. The two
SNPs in FXN found to be associated with MI are located in the 39
untranslated region of FXN (rs10890) and in a putative
transcription factor binding site (rs3793456), thus one or both of
these SNPs could have an effect on FXN gene expression. These
two SNPs are in linkage disequilibrium (r2 = 0.57 in Study 1) and
thus, are not independent of one another. Whether these SNPs are
associated with increased sensitivity of mitochondria to oxidative
stress or to other mild manifestations of Friedreich’s Ataxia
symptoms is not known.
The fourth SNP (rs3798220 in LPA) encodes a isoleucine to
methionine substitution at amino acid 4399 of apolipoprotein(a).
We have previously shown that this SNP is associated with
coronary artery narrowing and with increased levels of plasma
lipoprotein(a) in case-control studies [10]. This SNP was also
associated with incident myocardial infarction in the Cardiovas-
cular Health Study, a population–based prospective study of about
5000 individuals aged 65 or older [14]. The low minor allele
frequency of this SNP in LPA (1% in the European American
population of CHS [14]) suggests that this SNP accounts for only a
small fraction of the total variability of plasma Lp(a) levels. Our
previous data showed that Lp(a) levels were 5.9-fold higher in
carriers of the 4399 methionine allele than in noncarriers [10]; and
high levels of Lp(a) are associated with an increased risk for MI
[15,16]. Additionally, one can speculate that the association of the
4399 methionine allele with increased risk of disease could also be
due to the isoleucine to methionine change in apolipoprotein(a)
that may result in a more deleterious form of Lp(a).
Lastly, the fifth SNP is in HLA-DPB2 (rs35410698) is also
associated with MI in this study. HLA-DPB2 is a pseudogene in the
Human Leukocyte Antigen (HLA) region. The HLA region is highly
polymorphic, gene rich region. Linkage disequilibrium in this region
can extend across hundred kilobases and encompass HLA as well as
non-HLA genes [17]. Therefore, additional genotyping of SNPs in
this region would be needed in order to know which gene variant in
this region could be associated with MI.
Limitations
We analyzed case–control studies that were retrospectively
collected and did not include fatal cases of MI. Therefore, SNPs
Table 3. Genotypic association of 5 SNPs in Study 3
Age and Sex adjusted Fully Adjusted
SNP (gene symbol) Genotype Cases n (%) Controls n (%) OR 90% CI P value OR 90% CI P value
rs1325920 AA 327 (71) 394 (65) 1.61 0.92–2.81 0.08 1.28 0.62–2.62 0.3
(ENO1) GA 120 (26) 186 (31) 1.25 0.70–2.22 0.3 1.20 0.57–2.54 0.3
GG 14 (3) 27 (4) ref ref
Additive 1.28 1.06–1.55 0.01 1.09 0.85–1.38 0.3
rs10890 TT 117 (25) 98 (16) 1.52 1.14–2.04 0.009 1.49 1.02–2.18 0.04
(FXN) CT 201 (44) 325 (54) 0.79 0.62–0.99 0.9 0.85 0.63–1.16 0.8
CC 143 (31) 183 (30) ref ref
Additive 1.18 1.02–1.37 0.03 1.18 0.98–1.42 0.07
rs3793456 GG 174 (38) 180 (30) 1.33 0.98–1.80 0.06 1.50 1.01–2.22 0.04
(FXN) AG 205 (45) 319 (53) 0.88 0.66–1.18 0.8 1.00 0.69–1.45 0.5
AA 78 (17) 107 (18) ref ref
Additive 1.21 1.04–1.40 0.02 1.26 1.05–1.53 0.02
rs35410698 GG 426 (92) 539 (89) 1.56 1.09–2.22 0.02 2.07 1.31–3.27 0.004
(HLA-DPB2) GA 36 (8) 70 (11) ref ref
Additive 1.46 1.03–2.06 0.04 1.79 1.14–2.81 0.02
rs3798220 CT 41 (9) 12 (2) 4.63 2.67–8.03 ,0.001 3.52 1.85–6.69 0.001
(LPA) TT 416 (91) 573 (98) ref ref
Additive 4.63 2.67–8.03 ,0.001 3.52 1.85–6.69 0.001
doi:10.1371/journal.pone.0002895.t003
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specifically associated with fatal MI would not have been
identified. There were some differences between the participants
in these three studies, specifically, Study 3 controls were recruited
from patients who underwent coronary catheterization, whereas
Study 1 and Study 2 controls were recruited from a lipid clinic
population and from community centers. Thus, SNPs that were
associated with MI in Study 1 and Study 2 but not in Study 3
might be explained by the differences between these studies. For
example, a SNP in THBS4 (rs1866389) that was found to be
associated with MI in Study 1 and Study 2 but not in Study 3, has
been previously reported to be associated with premature MI [18].
However, the power to detect the association of THBS4 with MI in
Study 3 was limited (40% power), thus the lack of association in
Study 3 may represent a false negative result. The false discovery
rate for the 5 SNPs that were associated with MI in Study 3 was
0.23. Thus we expect that some of the SNPs we identified could be
false positive associations (type 1 error); replication from additional
studies is required to validate the observed associations. We have
looked for support for these associations in the published data from
the Welcome Trust Case-Control Consortium data [19], unfor-
tunately, none of the 5 SNPs we report here was genotyped in that
study. Finally, although the SNPs in this study could potentially
affect gene function, additional linkage disequilibrium analysis
would be needed in order to determine if other SNPs in these
region could better account for the associations with MI we
observed.
Conclusion
We identified 5 SNPs in 4 genes that are likely associated with
MI. These SNPs merit investigation in additional studies of MI.
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